DWTX Dogwood Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1818844 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY34.1%
TTM EPS YoY140.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-70.5%
ROA-30.0%
ROIC (approx.)-78.2%
Asset turnover—
Leverage & solvency
Liabilities / assets15.2%
Debt / equity0.00x
Current ratio2.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $100,000 | — | — | — | — | — | — | — |
| Cost of revenue | $88,104 | — | — | — | — | — | — | — |
| Gross profit | $11,896 | — | — | — | — | — | — | — |
| R&D expense | $3.35M | $3.25M | $2.67M | $2.34M | $14.52M | $2.57M | $2.44M | $2.32M |
| SG&A expense | $1.58M | $1.63M | $2.41M | $1.47M | $1.29M | $1.35M | $1.99M | $5.23M |
| Operating income | -$4.92M | -$14.06M | -$5.08M | -$3.81M | -$15.81M | -$3.92M | -$4.43M | -$7.54M |
| Pretax income | -$4.88M | -$14.01M | -$4.99M | -$3.75M | -$15.75M | -$3.81M | -$10.73M | -$7.73M |
| Net income | -$4.88M | -$11.53M | -$4.99M | -$3.78M | -$15.74M | -$3.81M | -$10.92M | -$7.73M |
| EBITDA | — | — | — | -$3.81M | -$15.84M | -$3.91M | -$4.41M | — |
| EPS (basic) | -0.14 | -0.34 | -0.15 | — | -8.20 | -1.99 | -8.45 | — |
| EPS (diluted) | -0.14 | -0.34 | -0.15 | — | -8.20 | -1.99 | -8.45 | — |
| Weighted avg. shares (diluted) | 34.13M | 34.13M | 33.54M | — | 1.92M | 1.91M | 1.44M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.95M | $9.61M | $13.23M | $6.52M | $10.13M | $13.40M | $17.54M | $14.85M |
| Current assets | $6.04M | $11.03M | $15.00M | $8.43M | $11.66M | $14.70M | $19.16M | $16.54M |
| PP&E, net | $12,320 | $12,301 | $12,541 | $12,754 | $15,293 | $16,179 | $15,899 | $16,811 |
| Goodwill | $11.98M | $11.96M | $12.19M | $12.40M | $12.21M | $12.46M | $11.82M | $11.81M |
| Intangibles | $57.44M | $57.35M | $67.83M | $68.99M | $67.92M | $69.30M | $65.77M | $65.71M |
| Total assets | $75.61M | $80.50M | $95.21M | $90.17M | $91.99M | $96.69M | $96.98M | $94.31M |
| Current liabilities | $2.17M | $2.83M | $2.56M | $3.06M | $2.60M | $1.89M | $2.58M | $3.18M |
| Total liabilities | $11.47M | $12.13M | $14.58M | $15.27M | $14.61M | $14.15M | $14.24M | $30.03M |
| Shareholders' equity | $64.13M | $68.37M | $80.62M | $74.90M | $7.26M | $6.88M | $7.09M | -$10.12M |
| Shares outstanding | 34.13M | 33.63M | 33.40M | 29.74M | 2.29M | 1.91M | 1.91M | 1.33M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.64M | -$3.61M | -$4.59M | -$3.64M | -$3.27M | -$4.03M | -$4.68M | -$6.13M |
| Financing cash flow | $50 | $23 | $11.29M | $32,561 | $0 | -$120,133 | $7.37M | $15.32M |
| Depreciation & amortization | — | — | — | $0 | -$32,215 | $17,256 | $17,022 | — |
| Stock-based compensation | $558,403 | $543,203 | $449,419 | $157,860 | $48,281 | $65,027 | $84,474 | $93,802 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.